ArticleLeukemia2020

OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis.

Lioubov Korotchkina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.